A comprehensive review of nanotechnology based drug delivery systems for osteoarthritis treatment
Source abstract
Abstract
Abstract The complex etiology and short-term positive effects of treatments for osteoarthritis (OA) remain a significant challenge globally. The lack of approved disease-modifying OA drugs (DMOADs) and the rapid clearance of intra-articular (IA) injections limit the treatment outcomes. Moreover, traditional therapy showed symptomatic relief and was limited by an accurate target and low drug bioavailability. In this view, nanotechnology-based drug delivery systems have been developed as a potential method to optimise therapeutic efficacy, targeted delivery, and minimise side effects in OA. These technologies provide better outcomes in regulating critical molecular pathways associated with OA progression, including the suppression of matrix metalloproteinases, inflammatory cytokines, and indicators of cartilage breakdown. A systematic literature search was conducted across PubMed, Scopus, Web of Science, and Embase using the keywords OA, drug delivery, biomaterials, and other nanocarriers, including nanoparticles, liposomes, and hydrogels, covering preclinical studies, clinical trials, and systematic reviews. The literature review presents current developments in nanocarriers and their applications for enhancing drug penetration and controlled release in joint tissues. Moreover, we emphasised the significance of nanocarrier-based drug delivery systems, including liposomes, micelles, dendrimers, and nanoparticle-based hydrogels, which are specifically engineered for OA treatment. The key findings indicated that nanocarriers can be designed to specifically target cartilage components, including aggrecans and collagen II, while effectively delivering various therapeutics such as anti-inflammatory agents, disease-modifying drugs, and gene therapies. Nanomicelles, nanohydrogels, and extracellular vesicles enabled optimised drug delivery to the specified target. The nanocarrier piroxicam gel was more effective at relieving pain due to its enhanced transdermal penetration. Oral nanomicelle-curcumin has reduced pain and stiffness compared with placebo. Nevertheless, challenges, including the reliability of biocompatibility, reduction of toxicity, and precise targeting, must be resolved to exploit their potential. Although preliminary clinical results with topical and oral nanoformulations are promising, future research should focus on long-term safety and on developing IA nanotherapies that demonstrate sustained release and chondroprotective properties.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Advancements in Transdermal Drug Delivery · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nursing 2nd Year Student, Sharda School of Nursing Science and Research, Sharda University , Greater Noida , India
Department of Medical Surgical Nursing , Sharda School of Nursing Science and Research, Sharda University , Greater Noida , India
Department of Software Engineering & Division of Electronics and Information Engineering , Jeonbuk National University , Jeonju-si , Republic of Korea
Department of Mental Health and Psychiatric Nursing, Faculty of Nursing , Al-Baha University , Al Baha , Saudi Arabia
References (100+)
Show source-provided references
1. Bannuru, RR, Schmid, CH, Kent, DM, Vaysbrot, EE, Wong, JB, McAlindon, TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015;162:46–54. https://doi.org/10.7326/m14-1231.10.7326/M14-1231 ↗
2. Mora, JC, Przkora, R, Cruz-Almeida, Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res 2018;5:2189–96. https://doi.org/10.2147/jpr.s154002.10.2147/JPR.S154002 ↗
3. Sharma, V, Anuvat, K, John, L, Davis, M. Scientific American pain management-arthritis of the knee. Decker: pain related disease states. 2017.10.2310/PM.15056 ↗
4. Kellgren, JH, Lawrence, JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494–502. https://doi.org/10.1136/ard.16.4.494.10.1136/ard.16.4.494 ↗
5. Richards, MM, Maxwell, JS, Weng, L, Angelos, MG, Golzarian, J. Intra-articular treatment of knee osteoarthritis: from anti-inflammatories to products of regenerative medicine. Physician Sportsmed 2016;44:101–8. https://doi.org/10.1080/00913847.2016.1168272.10.1080/00913847.2016.1168272 ↗
6. Chen, DI, Shen, J, Zhao, W, Wang, T, Han, L, Hamilton, JL, et al.. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res 2017;5:1–3. https://doi.org/10.1038/boneres.2016.44.10.1038/boneres.2016.44 ↗
7. Felson, DT, Naimark, A, Anderson, J, Kazis, L, Castelli, W, Meenan, RF. The prevalence of knee osteoarthritis in the elderly. The framingham osteoarthritis study. Arthritis Rheum Off J Am Coll Rheumatol 1987;30:914–8. https://doi.org/10.1002/art.1780300811.10.1002/art.1780300811 ↗
8. Jordan, JM, Helmick, CG, Renner, JB, Luta, G, Dragomir, AD, Woodard, J, et al.. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol 2007;34:172–80.
9. Dillon, CF, Rasch, EK, Gu, Q, Hirsch, R. Prevalence of knee osteoarthritis in the United States: arthritis data from the third national health and Nutrition Examination Survey 1991-94. J Rheumatol 2006;33:2271–9.
10. Loeser, RF. Aging and osteoarthritis. Curr Opin Rheumatol 2011;23:492–6. https://doi.org/10.1097/bor.0b013e3283494005.10.1097/BOR.0b013e3283494005 ↗
11. Kim, J, Xu, M, Xo, R, Mates, A, Wilson, GL, Pearsall, IVAW, et al.. Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes. Osteoarthr Cartil 2010;18:424–32. https://doi.org/10.1016/j.joca.2009.09.008.10.1016/j.joca.2009.09.008 ↗
12. Goodwin, W, McCabe, D, Sauter, E, Reese, E, Walter, M, Buckwalter, JA, et al.. Rotenone prevents impact‐induced chondrocyte death. J Orthop Res 2010;28:1057–63. https://doi.org/10.1002/jor.21091.10.1002/jor.21091 ↗
13. Xia, B, Chen, D, Zhang, J, Hu, S, Jin, H, Tong, P. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int 2014;95:495–505. https://doi.org/10.1007/s00223-014-9917-9.10.1007/s00223-014-9917-9 ↗
14. Goldring, MB, Goldring, SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010;1192:230–7. https://doi.org/10.1111/j.1749-6632.2009.05240.x.10.1111/j.1749-6632.2009.05240.x ↗
15. Mort, JS, Billington, CJ. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res Ther 2001;3:1–5.10.1186/ar325 ↗
16. Km, C. Gene deletion of either IL-1β, IL-1β-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003;48:3452–63.10.1002/art.11355 ↗
17. Li, Y, Xu, L, Olsen, BR. Lessons from genetic forms of osteoarthritis for the pathogenesis of the disease. Osteoarthr Cartil 2007;15:1101–5. https://doi.org/10.1016/j.joca.2007.04.013.10.1016/j.joca.2007.04.013 ↗
18. Kannu, P, Bateman, JF, Belluoccio, D, Fosang, AJ, Savarirayan, R. Employing molecular genetics of chondrodysplasias to inform the study of osteoarthritis. Arthritis Rheum Off J Am Coll Rheumatol 2009;60:325–34. https://doi.org/10.1002/art.24251.10.1002/art.24251 ↗
19. van der Kraan, PM, Goumans, MJ, Blaney Davidson, E, Ten Dijke, P. Age-dependent alteration of TGF-β signalling in osteoarthritis. Cell Tissue Res 2012;347:257–65. https://doi.org/10.1007/s00441-011-1194-6.10.1007/s00441-011-1194-6 ↗
20. Kolpakova, E, Olsen, BR. Wnt/β-catenin – a canonical tale of cell-fate choice in the vertebrate skeleton. Dev Cell 2005;8:626–7. https://doi.org/10.1016/j.devcel.2005.04.008.10.1016/j.devcel.2005.04.008 ↗
21. Degnin, CR, Laederich, MB, Horton, WA. FGFs in endochondral skeletal development. J Cell Biochem 2010;110:1046–57. https://doi.org/10.1002/jcb.22629.10.1002/jcb.22629 ↗
22. Schmidt, MB, Chen, EH, Lynch, SE. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthr Cartil 2006;14:403–12. https://doi.org/10.1016/j.joca.2005.10.011.10.1016/j.joca.2005.10.011 ↗
23. Davidson, EB, Vitters, EL, Van Der Kraan, PM, Van, DBWB. Expression of transforming growth factor-β (TGFβ) and the TGFβ signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Ann Rheum Dis 2006;65:1414–21. https://doi.org/10.1136/ard.2005.045971.10.1136/ard.2005.045971 ↗
24. Zhen, G, Wen, C, Jia, X, Li, Y, Crane, JL, Mears, SC, et al.. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 2013;19:704–12. https://doi.org/10.1038/nm.3143.10.1038/nm.3143 ↗
25. Fortier, LA, Barker, JU, Strauss, EJ, McCarrel, TM, Cole, BJ. The role of growth factors in cartilage repair. Clin Orthop Relat Res® 2011;469:2706–15. https://doi.org/10.1007/s11999-011-1857-3.10.1007/s11999-011-1857-3 ↗
26. Chia, SL, Sawaji, Y, Burleigh, A, McLean, C, Inglis, J, Saklatvala, J, et al.. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS‐5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheum off J Am Coll Rheumatol 2009;60:2019–27. https://doi.org/10.1002/art.24654.10.1002/art.24654 ↗
27. Cucchiarini, M, Terwilliger, EF, Kohn, D, Madry, H. Remodelling of human osteoarthritic cartilage by FGF‐2, alone or combined with Sox9 via rAAV gene transfer. J Cell Mol Med 2009;13:2476–88. https://doi.org/10.1111/j.1582-4934.2008.00474.x.10.1111/j.1582-4934.2008.00474.x ↗
28. Lee, AS, Ellman, MB, Yan, D, Kroin, JS, Cole, BJ, van Wijnen, AJ, et al.. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene 2013;527:440–7. https://doi.org/10.1016/j.gene.2013.05.069.10.1016/j.gene.2013.05.069 ↗
29. Ghosh, P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. InSeminars Arthritis Rheum 1999;28:211–67. https://doi.org/10.1016/s0049-0172(99)80021-3.10.1016/S0049-0172(99)80021-3 ↗
30. Evans, CH, Watkins, SC, Stefanović-Račić, M. Nitric oxide and cartilage metabolism. Methods Enzymol 1996;269:75–88. https://doi.org/10.1016/s0076-6879(96)69011-9.10.1016/S0076-6879(96)69011-9 ↗
31. Ghosh, P, Smith, M. Osteoarthritis, genetic and molecular mechanisms. Biogerontology 2002;3:85–8. https://doi.org/10.1023/a:1015219716583.10.1023/A:1015219716583 ↗
32. Zhang, Y, McAlindon, TE, Hannan, MT, Chaisson, CE, Klein, R, Wilson, PW, et al.. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham study. Arthritis Rheum Off J Am Coll Rheumatol 1998;41:1867–73. https://doi.org/10.1002/1529-0131(199810)41:10<1867::aid-art20>3.3.co;2-n.10.1002/1529-0131(199810)41:10<1867::AID-ART20>3.3.CO;2-N ↗
33. Nevitt, MC, Lane, NE, Scott, JC, Hochberg, MC, Pressman, AR, Genant, HK, et al.. Radiographic osteoarthritis of the hip and bone mineral density. Arthritis Rheum Off J Am Coll Rheumatol 1995;38:907–16. https://doi.org/10.1002/art.1780380706.10.1002/art.1780380706 ↗
34. Felson, DT, Zhang, Y, Anthony, JM, Naimark, A, Anderson, JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women: the framingham study. Ann Intern Med 1992;116:535–9. https://doi.org/10.7326/0003-4819-116-7-535.10.7326/0003-4819-116-7-535 ↗
35. Kohatsu, N, Schurman, D. Risk factors for the development of osteoarthrosis of the knee. Clin Orthop Relat Res 1990;261:242–6. https://doi.org/10.1097/00003086-199012000-00028.10.1097/00003086-199012000-00028 ↗
36. Kivitz, A, Eisen, G, Zhao, WW, Bevirt, T, Recker, DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51:530–7.
37. Dingle, JT. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol 1999;58:125–9. https://doi.org/10.1007/s003930050161.10.1007/s003930050161 ↗
38. El, HH, Marcelis, A, Devogelaer, JP, Manicourt, DH. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 2003;30:2444–51.
39. Yang, KA, Saris, DB, Dhert, WJ, Verbout, AJ. Osteoarthritis of the knee: current treatment options and future directions. Curr Orthop 2004;18:311–20. https://doi.org/10.1016/j.cuor.2004.04.005.10.1016/j.cuor.2004.04.005 ↗
40. Balazs, EA, Denlinger, JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. Supplement 1993;39:3–9.
41. Leopold, SS, Redd, BB, Warme, WJ, Wehrle, PA, Pettis, PD, Shott, S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee: a prospective, randomized trial. JBJS 2003;85:1197–203. https://doi.org/10.2106/00004623-200307000-00003.10.2106/00004623-200307000-00003 ↗
42. Leardini, G, Mattara, L, Franceschini, M, Perbellini, A. Intra-articular treatment of knee osteoarthritis. A comparative study between hyaluronic acid and 6-methyl prednisolone acetate. Clin Exp Rheumatol 1991;9:375–81.
43. Jackson, DW, Evans, NA, Thomas, BM. Accuracy of needle placement into the intra-articular space of the knee. JBJS 2002;84:1522–7. https://doi.org/10.2106/00004623-200209000-00003.10.2106/00004623-200209000-00003 ↗
44. Steadman, JR, Briggs, KK, Rodrigo, JJ, Kocher, MS, Gill, TJ, Rodkey, WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthrosc J Arthrosc Relat Surg 2003;19:477–84. https://doi.org/10.1053/jars.2003.50112.10.1053/jars.2003.50112 ↗
45. Peterson, L, Minas, T, Brittberg, M, Nilsson, A, Sjögren-Jansson, E, Lindahl, A. Two-to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 2000;374:212–34. https://doi.org/10.1097/00003086-200005000-00020.10.1097/00003086-200005000-00020 ↗
46. Bentley, G, Biant, LC, Carrington, RW, Akmal, M, Goldberg, A, Williams, AM, et al.. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. J Bone Jt Surg Br 2003;85:223–30. https://doi.org/10.1302/0301-620x.85b2.13543.10.1302/0301-620X.85B2.13543 ↗
47. Richard, MJ, Driban, JB, McAlindon, TE. Pharmaceutical treatment of osteoarthritis. Osteoarthr Cartil 2023;31:458–66. https://doi.org/10.1016/j.joca.2022.11.005.10.1016/j.joca.2022.11.005 ↗
48. Scott, PA, Kingsley, GH, Smith, CM, Choy, EH, Scott, DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007;66:1296–304. https://doi.org/10.1136/ard.2006.068650.10.1136/ard.2006.068650 ↗
49. Ioannidis, JP, Haidich, AB, Pappa, M, Pantazis, N, Kokori, SI, Tektonidou, MG, et al.. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821–30. https://doi.org/10.1001/jama.286.7.821.10.1001/jama.286.7.821 ↗
50. Cooper, C, Chapurlat, R, Al-Daghri, N, Herrero-Beaumont, G, Bruyère, O, Rannou, F, et al.. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging 2019;36:15–24. https://doi.org/10.1007/s40266-019-00660-1.10.1007/s40266-019-00660-1 ↗
51. Kolasinski, SL, Neogi, T, Hochberg, MC, Oatis, C, Guyatt, G, Block, J, et al.. American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020;72:220–33. https://doi.org/10.1002/art.41142.10.1002/art.41142 ↗
52. Dajani, EZ, Islam, K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 2008;59:117–33.
53. Harris, RC, Breyer, MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 2006;1:236–45. https://doi.org/10.2215/cjn.00890805.10.2215/CJN.00890805 ↗
54. Kijowski, R. Risks and benefits of intra-articular corticosteroid injection for treatment of osteoarthritis: what radiologists and patients need to know. Radiology 2019;293:664–5. https://doi.org/10.1148/radiol.2019192034.10.1148/radiol.2019192034 ↗
55. McAlindon, TE, LaValley, MP, Harvey, WF, Price, LL, Driban, JB, Zhang, M, et al.. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 2017;317:1967–75. https://doi.org/10.1001/jama.2017.5283.10.1001/jama.2017.5283 ↗
56. Anand, P, Bley, K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490–502. https://doi.org/10.1093/bja/aer260.10.1093/bja/aer260 ↗
57. Babbar, S, Marier, JF, Mouksassi, MS, Beliveau, M, Vanhove, GF, Chanda, S, et al.. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit 2009;31:502–10. https://doi.org/10.1097/ftd.0b013e3181a8b200.10.1097/FTD.0b013e3181a8b200 ↗
58. Craciunescu, O, Icriverzi, M, Florian, PE, Roseanu, A, Trif, M. Mechanisms and pharmaceutical action of lipid nanoformulation of natural bioactive compounds as efficient delivery systems in the therapy of osteoarthritis. Pharmaceutics 2021;13:1108. https://doi.org/10.3390/pharmaceutics13081108.10.3390/pharmaceutics13081108 ↗
59. Wen, J, Li, H, Dai, H, Hua, S, Long, X, Li, H, et al.. Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management. Mater Today Bio 2023;19:100597. https://doi.org/10.1016/j.mtbio.2023.100597.10.1016/j.mtbio.2023.100597 ↗
60. Huang, K, Li, Q, Lin, H, Shen, Q, Wu, Y, Tian, T, et al.. Cartilage‐penetrating framework nucleic acid nanoparticles ameliorate osteoarthritis by promoting drug delivery and chondrocyte uptake. Adv Sci 2025;12:2502661. https://doi.org/10.1002/advs.202502661.10.1002/advs.202502661 ↗
61. Morici, L, Allémann, E, Rodríguez-Nogales, C, Jordan, O. Cartilage-targeted drug nanocarriers for osteoarthritis therapy. Int J Pharm 2024;666:124843. https://doi.org/10.1016/j.ijpharm.2024.124843.10.1016/j.ijpharm.2024.124843 ↗
62. Shi, T, Zhao, J, Long, K, Gao, M, Chen, F, Chen, X, et al.. Cationic mesoporous silica nanoparticles alleviate osteoarthritis by targeting multiple inflammatory mediators. Biomaterials 2023;303:122366. https://doi.org/10.1016/j.biomaterials.2023.122366.10.1016/j.biomaterials.2023.122366 ↗
63. Xu, YD, Liang, XC, Li, ZP, Wu, ZS, Yang, J, Jia, SZ, et al.. Apoptotic body-inspired nanotherapeutics efficiently attenuate osteoarthritis by targeting BRD4-regulated synovial macrophage polarization. Biomaterials 2024;306:122483. https://doi.org/10.1016/j.biomaterials.2024.122483.10.1016/j.biomaterials.2024.122483 ↗
64. Wang, D, Pan, Y, Chen, W, He, D, Qi, W, Chen, J, et al.. Nanodrugs targeting key factors of ferroptosis regulation for enhanced treatment of osteoarthritis. Adv Sci 2025;12:2412817. https://doi.org/10.1002/advs.202412817.10.1002/advs.202412817 ↗
65. Zhan, M, Sun, H, Wang, Z, Li, G, Yang, R, Mignani, S, et al.. Nanoparticle-mediated multiple modulation of bone microenvironment to tackle osteoarthritis. ACS Nano 2024;18:10625–41. https://doi.org/10.1021/acsnano.4c00909.10.1021/acsnano.4c00909 ↗
66. Sheng, W, Li, A, Yue, Y, Wang, Q, Yu, F, Weng, J, et al.. A novel curcumin‐loaded nanoplatform alleviates osteoarthritis by inhibiting chondrocyte ferroptosis. Macromol Rapid Commun 2025;46:2400495. https://doi.org/10.1002/marc.202400495.10.1002/marc.202400495 ↗
67. Xue, X, Liu, H, Wang, S, Hu, Y, Huang, B, Li, M, et al.. Neutrophil-erythrocyte hybrid membrane-coated hollow copper sulfide nanoparticles for targeted and photothermal/anti-inflammatory therapy of osteoarthritis. Compos B Eng 2022;237:109855. https://doi.org/10.1016/j.compositesb.2022.109855.10.1016/j.compositesb.2022.109855 ↗
68. Xue, S, Ruan, G, Li, J, Madry, H, Zhang, C, Ding, C. Bio-responsive and multi-modality imaging nanomedicine for osteoarthritis theranostics. Biomater Sci 2023;11:5095–107. https://doi.org/10.1039/d3bm00370a.10.1039/D3BM00370A ↗
69. Xue, C, Tian, J, Cui, Z, Liu, Y, Sun, D, Xiong, M, et al.. Reactive oxygen species (ROS)-mediated M1 macrophage-dependent nanomedicine remodels inflammatory microenvironment for osteoarthritis recession. Bioact Mater 2024;33:545–61. https://doi.org/10.1016/j.bioactmat.2023.10.032.10.1016/j.bioactmat.2023.10.032 ↗
70. Lu, H, Wei, J, Liu, K, Li, Z, Xu, T, Yang, D, et al.. Radical-scavenging and subchondral bone-regenerating nanomedicine for osteoarthritis treatment. ACS Nano 2023;17:6131–46. https://doi.org/10.1021/acsnano.3c01789.10.1021/acsnano.3c01789 ↗
71. Lu, F, Wu, SH, Hung, Y, Mou, CY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 2009;5:1408–13. https://doi.org/10.1002/smll.200900005.10.1002/smll.200900005 ↗
72. Trewyn, BG, Nieweg, JA, Zhao, Y, Lin, VS. Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration. Chem Eng J 2008;137:23–9. https://doi.org/10.1016/j.cej.2007.09.045.10.1016/j.cej.2007.09.045 ↗
73. Moghimi, SM, Hunter, AC, Murray, JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283–318. https://doi.org/10.1016/s0031-6997(24)01494-7.10.1016/S0031-6997(24)01494-7 ↗
74. Panyam, J, Dali, MM, Sahoo, SK, Ma, W, Chakravarthi, SS, Amidon, GL, et al.. Polymer degradation and in vitro release of a model protein from poly (D, L-lactide-co-glycolide) nano-and microparticles. J Contr Release 2003;92:173–87. https://doi.org/10.1016/s0168-3659(03)00328-6.10.1016/S0168-3659(03)00328-6 ↗
75. Jeong, JH, Kim, SW, Park, TG. Molecular design of functional polymers for gene therapy. Prog Polym Sci 2007;32:1239–74. https://doi.org/10.1016/j.progpolymsci.2007.05.019.10.1016/j.progpolymsci.2007.05.019 ↗
76. Samad, A, Sultana, Y, Aqil, M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4:297–305. https://doi.org/10.2174/156720107782151269.10.2174/156720107782151269 ↗
77. Liu, Z, Li, X, Xiu, B, Duan, C, Li, J, Zhang, X, et al.. A novel and simple preparative method for uniform-sized PLGA microspheres: preliminary application in antitubercular drug delivery. Colloids Surf B Biointerfaces 2016;145:679–87. https://doi.org/10.1016/j.colsurfb.2016.05.085.10.1016/j.colsurfb.2016.05.085 ↗
78. Tabata, Y, Ikada, Y. Phagocytosis of polymer microspheres by macrophages. New Polym Mater 2005;10:107–41.10.1007/BFb0043062 ↗
79. Geng, YA, Dalhaimer, P, Cai, S, Tsai, R, Tewari, M, Minko, T, et al.. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007;2:249–55. https://doi.org/10.1038/nnano.2007.70.10.1038/nnano.2007.70 ↗
80. Nishiyama, N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2007;2:203–4. https://doi.org/10.1038/nnano.2007.88.10.1038/nnano.2007.88 ↗
81. Hodes, G. When small is different: some recent advances in concepts and applications of nanoscale phenomena. Adv Mater 2007;19:639–55. https://doi.org/10.1002/adma.200790035.10.1002/adma.200601173 ↗
82. Auffan, M, Rose, J, Bottero, JY, Lowry, GV, Jolivet, JP, Wiesner, MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 2009;4:634–41. https://doi.org/10.1038/nnano.2009.242.10.1038/nnano.2009.242 ↗
83. Sharma, D, Sharma, N, Pathak, M, Agrawala, PK, Basu, M, Ojha, H. Nanotechnology-based drug delivery systems: challenges and opportunities. Drug Target Stimuli Sensitive Drug Deliv Syst 2018;1:39–79.10.1016/B978-0-12-813689-8.00002-1 ↗
84. Prakash, S, Kulamarva, AG. Recent advances in drug delivery: potential and limitations of carbon nanotubes. Recent Pat Drug Deliv Formul 2007;1:214–2. https://doi.org/10.2174/187221107782331601.10.2174/187221107782331601 ↗
85. Salata, OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnol 2004;2:1–6. https://doi.org/10.1186/1477-3155-2-3.10.1186/1477-3155-2-3 ↗
86. Ravichandran, R. Nanotechnology-based drug delivery systems. NanoBiotechnology 2009;5:17–33. https://doi.org/10.1007/s12030-009-9028-2.10.1007/s12030-009-9028-2 ↗
87. Keck, CM, Müller, RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3–16. https://doi.org/10.1016/j.ejpb.2005.05.009.10.1016/j.ejpb.2005.05.009 ↗
88. Thassu, D, Pathak, Y, Deleers, M. Nanoparticulate drug delivery systems. an overview. In: Thassu D, Deleers M, Pathak Y, editors. Nanoparticulate drug delivery systems. New York: Informa Healthcare; 2007:1–31 pp.”10.1201/9781420008449-1 ↗
89. Shinde, AJ, Tyagi, R. Solubilization of poorly soluble drugs: a review. Pharmainfo. net 2007;5:36–44.
90. Chaubal, MV. Application of formulation technologies in lead candidate selection and optimization. Drug Discov Today 2004;9:603–9. https://doi.org/10.1016/s1359-6446(04)03171-x.10.1016/S1359-6446(04)03171-X ↗
91. Basa, S, Muniyappan, T, Karatgi, P, Prabhu, R, Pillai, R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm 2008;34:1209–18. https://doi.org/10.1080/03639040802005024.10.1080/03639040802005024 ↗
92. Muller, RH. Nanosuspension for the formulation of poorly soluble drugs. In: Neilloud, F and Marti-Mestres, G, editors, pharmaceutical emulsion and suspension.
93. Mozafari, M. Nanotechnology in wound care: one step closer to the clinic. Mol Ther 2018;26:2085–6. https://doi.org/10.1016/j.ymthe.2018.08.008.10.1016/j.ymthe.2018.08.008 ↗
94. Bobo, D, Robinson, KJ, Islam, J, Thurecht, KJ, Corrie, SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 2016;33:2373–87. https://doi.org/10.1007/s11095-016-1958-5.10.1007/s11095-016-1958-5 ↗
95. Sahu, T, Ratre, YK, Chauhan, S, Bhaskar, LV, Nair, MP, Verma, HK. Nanotechnology based drug delivery system: current strategies and emerging therapeutic potential for medical science. J Drug Deliv Sci Technol 2021;63:102487. https://doi.org/10.1016/j.jddst.2021.102487.10.1016/j.jddst.2021.102487 ↗
96. Bajracharya, R, Song, JG, Back, SY, Han, HK. Recent advancements in non-invasive formulations for protein drug delivery. Comput Struct Biotechnol J 2019;17:1290–308. https://doi.org/10.1016/j.csbj.2019.09.004.10.1016/j.csbj.2019.09.004 ↗
97. Laura, IM, Dosio, F, Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J nanomedicine 2006;1:297–315.
98. Akbarzadeh, A, Rezaei-Sadabady, R, Davaran, S, Joo, SW, Zarghami, N, Hanifehpour, Y, et al.. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013;8:1–9. https://doi.org/10.1186/1556-276x-8-102.10.1186/1556-276X-8-102 ↗
99. Kedar, U, Phutane, P, Shidhaye, S, Kadam, V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med 2010;6:714–29. https://doi.org/10.1016/j.nano.2010.05.005.10.1016/j.nano.2010.05.005 ↗
100. Kahraman, E, Güngör, S, Özsoy, Y. Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery. Ther Deliv 2017;8:967–85. https://doi.org/10.4155/tde-2017-0075.10.4155/tde-2017-0075 ↗